NFKB inhibitor interacting Ras like 2Genealiases: KBRAS2 · kappaB-Ras2
Q-omics provides the consensus-scored NKIRAS2 profile across patient tissues and cancer cell-line models. NKIRAS2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, NKIRAS2 is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, NKIRAS2 RNA expression shows 19,170 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight BLCA, KIRC, and ACC as cancer lineages where NKIRAS2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NKIRAS2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NKIRAS2 survival associations across molecular data types. NKIRAS2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NKIRAS2 RNA expression–survival associations across cancer types. High NKIRAS2 expression shows unfavorable associations in BLCA, ACC, MESO, LIHC and KIRP, but favorable associations in UVM. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for NKIRAS2 RNA expression.
This table summarizes NKIRAS2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for NKIRAS2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NKIRAS2 shows lower tumor expression in KICH and higher tumor expression in KIRC, HNSC, KIRP, LIHC and LUSC. The KIRC box plot shows higher NKIRAS2 RNA expression in tumor versus normal tissue (log2 FC = +0.802, t-test p < 0.001).
This table shows molecular features associated with NKIRAS2 in patient tissues and cancer cell lines. In patient samples, NKIRAS2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, NKIRAS2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in LIVER and UPPER_AERODIGESTIVE_TRACT.
